传统上,HER2阳性乳腺癌被认为是治疗上困难的一类,尤其是在转移性阶段。现有的一线治疗主要依赖于帕妥珠单抗(Perjeta)这类药物,它为患者提供了新的生存机会。HLX11作为复宏汉霖的自主研发产品,目标是为这些患者提供一个可能更加经济的生物类似药选项。
“Early administration of this combination may eliminate the need for polychemotherapy, minimize toxicity, and improve long-term outcomes for patients with early stage, HER2-positive breast ...
Proteolytic Cleavage of HER2 (Ectodomain Shedding) & the Generation of Neoepitopes as New Biomarker Targets Proteolytic cleavage of HER2 (p185) has been demonstrated to result in a 95-kD (p95) CTF ...
NEW YORK – During a call on Thursday to discuss Roche's fourth quarter 2024 financial performance, company executives were optimistic that regulators in the EU will approve Itovebi (inavolisib) in the ...
These participants were randomly assigned to treatment with either a combination of the HER2 inhibitors trastuzumab (Herceptin ®) and pertuzumab (Perjeta ®) (TP) every three weeks or a standard ...
Research is underway on the immune-stimulating antibody conjugate BDC-1001’s effectiveness against HER2-positive cancers when combined with Perjeta, according to data presented at SABCS. The Food and ...
Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer after endocrine therapy progression, based on DESTINY-Breast06 trial results. Enhertu showed a 36% reduction in ...
In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...
Since 2022, Enhertu has been approved in the U.S. to treat advanced breast tumors expressing “low,” but still detectable, levels of the HER2 protein. With its new decision, the agency widened ...
T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in patients whose disease progressed on prior endocrine therapy in the metastatic ...
Trastuzumab with chemotherapy showed numerical improvements in overall survival and progression-free survival in HER2-positive gastric and gastroesophageal junction cancers. Trastuzumab (Herceptin) ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果